open access

Vol 68, No 2 (2017)
REVIEWS — Postgraduate Education
Published online: 2017-05-08
Submitted: 2017-04-04
Accepted: 2017-04-05
Get Citation

Neuroendocrine neoplasms of the small intestine and appendix — management guidelines (recommended by the Polish Network of Neuroendocrine Tumours)

Tomasz Bednarczuk, Marek Bolanowski, Anna Zemczak, Agata Bałdys-Waligórska, Jolanta Blicharz-Dorniak, Agnieszka Boratyn-Nowicka, Małgorzata Borowska, Andrzej Cichocki, Jarosław B. Ćwikła, Massimo Falconi, Wanda Foltyn, Daria Handkiewicz-Junak, Alicja Hubalewska-Dydejczyk, Barbara Jarząb, Roman Junik, Dariusz Kajdaniuk, Grzegorz Kamiński, Agnieszka Kolasińska-Ćwikła, Aldona Kowalska, Robert Król, Leszek Królicki, Jolanta Kunikowska, Katarzyna Kuśnierz, Paweł Lampe, Dariusz Lange, Anna Lewczuk-Myślicka, Andrzej Lewiński, Michał Lipiński, Magdalena Londzin-Olesik, Bogdan Marek, Anna Nasierowska-Guttmejer, Ewa Nowakowska-Duława, Jakub Pałucki, Joanna Pilch-Kowalczyk, Violetta Rosiek, Marek Ruchała, Lucyna Siemińska, Anna Sowa-Staszczak, Teresa Starzyńska, Katarzyna Steinhof-Radwańska, Janusz Strzelczyk, Krzysztof Sworczak, Anhelli Syrenicz, Andrzej Szawłowski, Marek Szczepkowski, Ewa Wachuła, Wojciech Zajęcki, Wojciech Zgliczyński, Beata Kos-Kudła
DOI: 10.5603/EP.2017.0018
·
Endokrynologia Polska 2017;68(2):223-236.

open access

Vol 68, No 2 (2017)
REVIEWS — Postgraduate Education
Published online: 2017-05-08
Submitted: 2017-04-04
Accepted: 2017-04-05

Abstract

This study presents the revised Polish guidelines regarding the management of patients suffering from neuroendocrine neoplasms (NENs) of the small intestine and appendix. The small intestine, especially the ileum, is the most common location for these neoplasms. Most are well differentiated and slow growing. Their symptoms may be atypical, which can result in delayed or accidental diagnosis. Appendicitis is usually the first manifestation of NEN in this location. Typical symptoms of carcinoid syndrome occur in approximately 20–30% of patients suffering from small intestinal NENs with distant metastases. The main cause of death in patients with carcinoid syndrome is carcinoid heart disease. The most useful laboratory test is the determination of chromogranin A, while concentration of 5-hydroxyindoleacetic acid is helpful in the diagnostics of carcinoid syndrome. For visualisation, ultrasound, computed tomography, magnetic resonance imaging, colonoscopy, video capsule endoscopy, double-balloon enteroscopy, and somatostatin receptor scintigraphy may be used. A detailed his­tological report is crucial for the proper diagnostics and therapy of NENs of the small intestine and appendix. The treatment of choice is surgical management, either radical or palliative. The pharmacological treatment of the hormonally active and non-active small intestinal NENs as well as NENs of the appendix is based on long-acting somatostatin analogues. In patients with generalised NENs of the small intestine in progress during the SSA treatment, with good expression of somatostatin receptors, the first-line treatment should be radio­isotope therapy, while targeted therapies, such as everolimus, should be considered afterwards. When the above therapies are exhausted, in certain cases chemotherapy may be considered.

Abstract

This study presents the revised Polish guidelines regarding the management of patients suffering from neuroendocrine neoplasms (NENs) of the small intestine and appendix. The small intestine, especially the ileum, is the most common location for these neoplasms. Most are well differentiated and slow growing. Their symptoms may be atypical, which can result in delayed or accidental diagnosis. Appendicitis is usually the first manifestation of NEN in this location. Typical symptoms of carcinoid syndrome occur in approximately 20–30% of patients suffering from small intestinal NENs with distant metastases. The main cause of death in patients with carcinoid syndrome is carcinoid heart disease. The most useful laboratory test is the determination of chromogranin A, while concentration of 5-hydroxyindoleacetic acid is helpful in the diagnostics of carcinoid syndrome. For visualisation, ultrasound, computed tomography, magnetic resonance imaging, colonoscopy, video capsule endoscopy, double-balloon enteroscopy, and somatostatin receptor scintigraphy may be used. A detailed his­tological report is crucial for the proper diagnostics and therapy of NENs of the small intestine and appendix. The treatment of choice is surgical management, either radical or palliative. The pharmacological treatment of the hormonally active and non-active small intestinal NENs as well as NENs of the appendix is based on long-acting somatostatin analogues. In patients with generalised NENs of the small intestine in progress during the SSA treatment, with good expression of somatostatin receptors, the first-line treatment should be radio­isotope therapy, while targeted therapies, such as everolimus, should be considered afterwards. When the above therapies are exhausted, in certain cases chemotherapy may be considered.

Get Citation

Keywords

nowotwory neuroendokrynne; zalecenia; jelito cienkie; wyrostek robaczkowy; zespół rakowiaka; analogi somatostatyny; terapia izotopowa PRRT; terapie celowane

About this article
Title

Neuroendocrine neoplasms of the small intestine and appendix — management guidelines (recommended by the Polish Network of Neuroendocrine Tumours)

Journal

Endokrynologia Polska

Issue

Vol 68, No 2 (2017)

Pages

223-236

Published online

2017-05-08

DOI

10.5603/EP.2017.0018

Bibliographic record

Endokrynologia Polska 2017;68(2):223-236.

Keywords

nowotwory neuroendokrynne
zalecenia
jelito cienkie
wyrostek robaczkowy
zespół rakowiaka
analogi somatostatyny
terapia izotopowa PRRT
terapie celowane

Authors

Tomasz Bednarczuk
Marek Bolanowski
Anna Zemczak
Agata Bałdys-Waligórska
Jolanta Blicharz-Dorniak
Agnieszka Boratyn-Nowicka
Małgorzata Borowska
Andrzej Cichocki
Jarosław B. Ćwikła
Massimo Falconi
Wanda Foltyn
Daria Handkiewicz-Junak
Alicja Hubalewska-Dydejczyk
Barbara Jarząb
Roman Junik
Dariusz Kajdaniuk
Grzegorz Kamiński
Agnieszka Kolasińska-Ćwikła
Aldona Kowalska
Robert Król
Leszek Królicki
Jolanta Kunikowska
Katarzyna Kuśnierz
Paweł Lampe
Dariusz Lange
Anna Lewczuk-Myślicka
Andrzej Lewiński
Michał Lipiński
Magdalena Londzin-Olesik
Bogdan Marek
Anna Nasierowska-Guttmejer
Ewa Nowakowska-Duława
Jakub Pałucki
Joanna Pilch-Kowalczyk
Violetta Rosiek
Marek Ruchała
Lucyna Siemińska
Anna Sowa-Staszczak
Teresa Starzyńska
Katarzyna Steinhof-Radwańska
Janusz Strzelczyk
Krzysztof Sworczak
Anhelli Syrenicz
Andrzej Szawłowski
Marek Szczepkowski
Ewa Wachuła
Wojciech Zajęcki
Wojciech Zgliczyński
Beata Kos-Kudła

References (110)
  1. Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev. 2004; 25(3): 458–511.
  2. Plöckinger U, Rindi G, Arnold R, et al. Guidelines for the diagnosis and treatment of neu-roendocrine gastrointestinal tumours. Neuroendocrinology. 2004; 80: 394–424.
  3. Bolanowski M, Bednarczuk T, Bobek-Billewicz B, et al. Consensus Conference, Polish Network of Neuroendocrine Tumours. Neuroendocrine neoplasms of the small intestine and the appendix - management guidelines (recommended by the Polish Network of Neuroendocrine Tumours). Endokrynol Pol. 2013; 64(6): 480–493.
  4. Niederle B, Pape UF, Costa F, et al. Vienna Consensus Conference participants. ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum. Neuroendocrinology. 2016; 103(2): 125–138.
  5. Pape UF, Perren A, Niederle B, et al. Barcelona Consensus Conference participants. ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas. Neuroendocrinology. 2012; 95(2): 135–156.
  6. Ellis L, Shale MJ, Coleman MP. Carcinoid tumors of the gastrointestinal tract: trends in incidence in England since 1971. Am J Gastroenterol. 2010; 105(12): 2563–2569.
  7. Yao JC, Hassan M, Phan A, et al. One hundred years after. J Clin Oncol. 2008; 26(18): 3063–3072.
  8. Ito T, Sasano H, Tanaka M, et al. Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol. 2010; 45(2): 234–243.
  9. Hauso O, Gustafsson BI, Kidd M, et al. Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer. 2008; 113(10): 2655–2664.
  10. Landerholm K, Falkmer S, Järhult J. Epidemiology of small bowel carcinoids in a defined population. World J Surg. 2010; 34(7): 1500–1505.
  11. Niederle MB, Hackl M, Kaserer K, et al. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocr Relat Cancer. 2010; 17(4): 909–918.
  12. Berge T, Linell F. Carcinoid tumours. Frequency in a defined population during a 12-year period. Acta Pathol Microbiol Scand A. 1976; 84(4): 322–330.
  13. Boxberger N, Redlich A, Böger C, et al. Neuroendocrine tumors of the appendix in children and adolescents. Pediatr Blood Cancer. 2013; 60(1): 65–70.
  14. Wu H, Chintagumpala M, Hicks J, et al. Neuroendocrine Tumor of the Appendix in Children. J Pediatr Hematol Oncol. 2017; 39(2): 97–102.
  15. Oberndorfer S. Karzinoide Tumoren des Dunndarms. Frankf Z Pathol. 1907; 1: 426–429.
  16. Klimstra DS, Modlin IR, Adsay NV, et al. Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set. Am J Surg Pathol. 2010; 34(3): 300–313.
  17. Lawrence B, Gustafsson BI, Chan A, et al. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am. 2011; 40(1): 1–18, vii.
  18. Fraenkel M, Kim M, Faggiano A, et al. Knowledge NETwork. Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature. Endocr Relat Cancer. 2014; 21(3): R153–R163.
  19. Ten Cate EM, Wong LA, Groff WL, et al. Post-surgical surveillance of locally advanced ileal carcinoids found by routine ileal intubation during screening colonoscopy: a case series. J Med Case Rep. 2014; 8: 444.
  20. Yarze JC, Herlihy KJ, Coombes JM, et al. Detection of asymptomatic ileal carcinoid tumors during ileal intubation at screening colonoscopy: a case series. Am J Gastroenterol. 2009; 104(12): 3114–3115.
  21. Jann H, Roll S, Couvelard A, et al. Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome. Cancer. 2011; 117(15): 3332–3341.
  22. Bordeaux JP, Klimstra DS, Hassan MM, et al. The NANETS consensus guideline for the di-agnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the jejunum, ileum, appendix, and caecum. Pancreas. 2010; 39: 753–766.
  23. Ramage JK, Ahmed A, Ardill J, et al. UK and Ireland Neuroendocrine Tumour Society. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut. 2012; 61(1): 6–32.
  24. Kaczmarska-Turek D, Pryć M, Kuś A, et al. Pitfalls in the diagnosis of carcinoid syndrome. Fam Med Prim Care Rev. 2016; 18: 109–113.
  25. Pearman TP, Beaumont JL, Cella D, et al. Health-related quality of life in patients with neuroendocrine tumors: an investigation of treatment type, disease status, and symptom burden. Support Care Cancer. 2016; 24(9): 3695–3703.
  26. Hannah-Shmouni F, Stratakis CA, Koch CA. Flushing in (neuro)endocrinology. Rev Endocr Metab Disord. 2016; 17(3): 373–380.
  27. Luis SA, Pellikka PA. Carcinoid heart disease: Diagnosis and management. Best Pract Res Clin Endocrinol Metab. 2016; 30(1): 149–158.
  28. Silaschi M, Barr J, Chaubey S, et al. Optimized Outcomes Using a Standardized Approach for Treatment of Patients with Carcinoid Heart Disease. Neuroendocrinology. [in press]
  29. Łepska L, Pisiak S, Dudziak M. A case of carcinoid pericardial metastases and massive effusion. Kardiol Pol. 2013; 71(8): 881.
  30. Bednarczuk T, Dębski M, Chojnowski K, et al. Carcinoid crisis. Med Prakt. 2009; 2: 164–169.
  31. Liu EH, Solorzano CC, Katznelson L, et al. AACE Endocrine Surgery Scientific Committee, AACE Endocrine Surgery Scientific Committee--Neuroendocrine Carcinoid Subgroup. AACE/ACE disease state clinical review: diagnosis and management of midgut carcinoids. Endocr Pract. 2015; 21(5): 534–545.
  32. Pape UF, Niederle B, Costa F, et al. Vienna Consensus Conference participants. ENETS Consensus Guidelines for Neuroendocrine Neoplasms of the Appendix (Excluding Goblet Cell Carcinomas). Neuroendocrinology. 2016; 103(2): 144–152.
  33. Mullen JT, Savarese DMF. Carcinoid tumors of the appendix: a population-based study. J Surg Oncol. 2011; 104(1): 41–44.
  34. Kanakis G, Kaltsas G. Biochemical markers for gastroenteropancreatic neuroendocrine tu-mours (GEP-NETs). Best Pract Res Clin Gastroenterol. 2012; 26: 791–802.
  35. Bolanowski M, Kos-Kudła B, Rzeszutko M, et al. [Five year remission of GHRH secreting bronchial neuroendocrine tumor with symptoms of acromegaly. Utility of chromogranin A in the monitoring of the disease]. Endokrynol Pol. 2006; 57(1): 32–36.
  36. Tian T, Gao J, Li N, et al. Circulating Chromogranin A as A Marker for Monitoring Clinical Re-sponse in Advanced Gastroenteropancreatic Neuroendocrine Tumors. PLoS One. 2016; 11: e0154679.
  37. Zandee WT, Kamp K, van Adrichem RCS, et al. Limited value for urinary 5-HIAA excretion as prognostic marker in gastrointestinal neuroendocrine tumours. Eur J Endocrinol. 2016; 175(5): 361–366.
  38. Dobson R, Burgess MI, Banks M, et al. The association of a panel of biomarkers with the presence and severity of carcinoid heart disease: a cross-sectional study. PLoS One. 2013; 8(9): e73679.
  39. Ćwikła JB, Bodei L, Kolasinska-Ćwikła A, et al. Circulating Transcript Analysis (NETest) in GEP-NETs Treated With Somatostatin Analogs Defines Therapy. J Clin Endocrinol Metab. 2015; 100(11): E1437–E1445.
  40. Miller HC, Frampton AE, Malczewska A, et al. MicroRNAs associated with small bowel neuroendocrine tumours and their metastases. Endocr Relat Cancer. 2016; 23(9): 711–726.
  41. Soyer P, Aout M, Hoeffel C, et al. Helical CT-enteroclysis in the detection of small-bowel tumours: a meta-analysis. Eur Radiol. 2013; 23(2): 388–399.
  42. Bonekamp D, Raman SP, Horton KM, et al. Role of computed tomography angiography in detection and staging of small bowel carcinoid tumors. World J Radiol. 2015; 7(9): 220–235.
  43. Ganeshan D, Bhosale P, Yang T, et al. Imaging features of carcinoid tumors of the gastrointestinal tract. AJR Am J Roentgenol. 2013; 201(4): 773–786.
  44. Faggian A, Fracella MR, D'Alesio G, et al. Small-Bowel Neoplasms: Role of MRI Enteroclysis. Gastroenterol Res Pract. 2016; 2016: 9686815.
  45. Casciani E, Polettini E, Laghi F, et al. Magnetic resonance imaging of small bowel neoplasms. Cancer Imaging. 2013; 13(1): 92–99.
  46. Smereczyński A, Starzyńska T, Kołaczyk K. Mesenteric changes in an ultrasound examination can facilitate the diagnosis of neuroendocrine tumors of the small intestine. J Ultrason. 2015; 15(62): 274–282.
  47. Leszczyński S, Pilch-Kowalczyk J. eds). Imaging diagnostics. Digestive system. : PZWL.
  48. Iacopini F, Saito Y, Gotoda T, et al. Endoscopic submucosal dissection of a nonpolypoid superficial neoplasm of the terminal ileum. Endoscopy. 2016; 48 Suppl 1 UCTN: E57–E58.
  49. van Tuyl SAC, van Noorden JT, Timmer R, et al. Detection of small-bowel neuroendocrine tumors by video capsule endoscopy. Gastrointest Endosc. 2006; 64(1): 66–72.
  50. Bailey AA, Debinski HS, Appleyard MN, et al. Diagnosis and outcome of small bowel tumors found by capsule endoscopy: a three-center Australian experience. Am J Gastroenterol. 2006; 101(10): 2237–2243.
  51. Bellutti M, Fry LC, Schmitt J, et al. Detection of neuroendocrine tumors of the small bowel by double balloon enteroscopy. Dig Dis Sci. 2009; 54(5): 1050–1058.
  52. Ricke J, Klose KJ, Mignon M, et al. Standardisation of imaging in neuroendocrine tumours: results of a European delphi process. Eur J Radiol. 2001; 37(1): 8–17.
  53. Hakim FA, Alexander JA, Huprich JE, et al. CT-enterography may identify small bowel tumors not detected by capsule endoscopy: eight years experience at Mayo Clinic Rochester. Dig Dis Sci. 2011; 56(10): 2914–2919.
  54. Frilling A, Smith G, Clift AK, et al. Capsule endoscopy to detect primary tumour site in metastatic neuroendocrine tumours. Dig Liver Dis. 2014; 46(11): 1038–1042.
  55. Strosberg JR, Shibata D, Kvols LK. Intermittent bowel obstruction due to a retained wireless capsule endoscope in a patient with a small bowel carcinoid tumour. Can J Gastroenterol. 2007; 21(2): 113–115.
  56. Johanssen S, Boivin M, Lochs H, et al. The yield of wireless capsule endoscopy in the detection of neuroendocrine tumors in comparison with CT enteroclysis. Gastrointest Endosc. 2006; 63(4): 660–665.
  57. Rondonotti E, Pennazio M, Toth E, et al. European Capsule Endoscopy Group, Italian Club for Capsule Endoscopy (CICE), Iberian Group for Capsule Endoscopy. Small-bowel neoplasms in patients undergoing video capsule endoscopy: a multicenter European study. Endoscopy. 2008; 40(6): 488–495.
  58. Yamamoto H, Kita H, Sunada K, et al. Clinical outcomes of double-balloon endoscopy for the diagnosis and treatment of small-intestinal disease. Clin Gastroenterol Hepatol. 2004; 2: 1010–1016.
  59. Pasha SF, Leighton JA, Das A, et al. Double-balloon enteroscopy and capsule endoscopy have comparable diagnostic yield in small-bowel disease: a meta-analysis. Clin Gastroenterol Hepatol. 2008; 6(6): 671–676.
  60. Chen J, Zhang L, Zhang W, et al. A Case of Neuroendocrine Malignant Tumor with Capsule Retention Diagnosed by Double-Balloon Enteroscopy. Case Rep Gastroenterol. 2010; 4(1): 52–56.
  61. Ethun CG, Postlewait LM, Baptiste GG, et al. Small bowel neuroendocrine tumors: A critical analysis of diagnostic work-up and operative approach. J Surg Oncol. 2016; 114(6): 671–676.
  62. Sulbaran M, de Moura E, Bernardo W, et al. Overtube-assisted enteroscopy and capsule endoscopy for the diagnosis of small-bowel polyps and tumors: a systematic review and meta-analysis. Endosc Int Open. 2016; 4(2): E151–E163.
  63. Elena RM, Riccardo U, Rossella C, et al. Current status of device-assisted enteroscopy: Technical matters, indication, limits and complications. World J Gastrointest Endosc. 2012; 4(10): 453–461.
  64. Krenning EP, Kwekkeboom DJ, Oei HY, et al. Somatostatin-receptor scintigraphy in gastroenteropancreatic tumors. An overview of European results. Ann N Y Acad Sci. 1994; 733: 416–424.
  65. Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993; 20(8): 716–731.
  66. Schreiter NF, Bartels AM, Froeling V, et al. Searching for primaries in patients with neuroendocrine tumors (NET) of unknown primary and clinically suspected NET: Evaluation of Ga-68 DOTATOC PET/CT and In-111 DTPA octreotide SPECT/CT. Radiol Oncol. 2014; 48(4): 339–347.
  67. Virgone C, Cecchetto G, Besutti V, et al. Appendiceal neuroendocrine tumours in childhood: Italian TREP project. J Pediatr Gastroenterol Nutr. 2014; 58(3): 333–338.
  68. Karpińska K, Nasierowska-Guttmejer A. Standardy Oceny Makroskopowej Materiału Biopsyj-nego i Operacyjnego U Chorych na Nowotwory Złośliwe. Polish Journal of Pathology. 2015; 66(supplement 1): 11–13.
  69. WHO Classification of Tumours of the Digestive System. IARC: 2017 (in press)
  70. Garcia-Carbonero R, Sorbye H, Baudin E, et al. ENETS Conscensus Guidelines for High-Grade Gastroenteropancreatic Neuroedocrine Carcinoma. Neuroendocrinology. 2016; 103: 186–194.
  71. Woltering EA, Bergsland EK, Beyer DT, et al. Neuroendocrine Tumors of the Appendix. Amer-ican Joint Committee on Cancer 2017. In: Amin M. B. (eds) AJCC Cancer Staging Manual. Eight Edition Springer 2017; 389-394 DOI 10 1007/978-3-319-40618-3. ; 30.
  72. Brierley JD, Gospodarowicz MK, Wittekind C, et al. eds). UICC TNM Classification of Malig-nant Tumours. Eight Edition. Wiley Blackwell. 2016; 201: 99–101.
  73. Bertani E, Falconi M, Grana C, et al. Small intestinal neuroendocrine tumors with liver metastases and resection of the primary: Prognostic factors for decision making. Int J Surg. 2015; 20: 58–64.
  74. Maxwell JE, Sherman SK, O'Dorisio TM, et al. Liver-directed surgery of neuroendocrine metastases: What is the optimal strategy? Surgery. 2016; 159(1): 320–333.
  75. Alexandraki KI, Kaltsas GA, Grozinsky-Glasberg S, et al. Appendiceal neuroendocrine neoplasms: diagnosis and management. Endocr Relat Cancer. 2016; 23(1): R27–R41.
  76. Jiang Y, Long Hu, Wang W, et al. Clinicopathological features and immunoexpression profiles of goblet cell carcinoid and typical carcinoid of the appendix. Pathol Oncol Res. 2011; 17(1): 127–132.
  77. Chetty R, Klimstra DS, Henson DE, et al. Combined classical carcinoid and goblet cell carcinoid tumor: a new morphologic variant of carcinoid tumor of the appendix. Am J Surg Pathol. 2010; 34(8): 1163–1167.
  78. Groth SS, Virnig BA, Al-Refaie WB, et al. Appendiceal carcinoid tumors: Predictors of lymph node metastasis and the impact of right hemicolectomy on survival. J Surg Oncol. 2011; 103(1): 39–45.
  79. Alexandraki KI, Griniatsos J, Bramis KI, et al. Clinical value of right hemicolectomy for appendiceal carcinoids using pathologic criteria. J Endocrinol Invest. 2011; 34(4): 255–259.
  80. Bamboat ZM, Berger DL. Is right hemicolectomy for 2.0-cm appendiceal carcinoids justified? Arch Surg. 2006; 141(4): 349–52; discussion 352.
  81. Mullen JT, Savarese DMF. Carcinoid tumors of the appendix: a population-based study. J Surg Oncol. 2011; 104(1): 41–44.
  82. Grozinsky-Glasberg S, Alexandraki KI, Barak D, et al. Current size criteria for the management of neuroendocrine tumors of the appendix: are they valid? Clinical experience and review of the literature. Neuroendocrinology. 2013; 98(1): 31–37.
  83. In't Hof KH, van der Wal HC, Kazemier G, et al. Carcinoid tumour of the appendix: an analysis of 1,485 consecutive emergency appendectomies. J Gastrointest Surg. 2008; 12(8): 1436–1438.
  84. Hsu C, Rashid A, Xing Y, et al. Varying malignant potential of appendiceal neuroendocrine tumors: importance of histologic subtype. J Surg Oncol. 2013; 107(2): 136–143.
  85. Volante M, Daniele L, Asioli F, et al. Tumor staging but not grading is associated with adverse clinical outome in neuroendocrine tumors of the appendix. Am J Surg Pathol. 2013; 37: 606-612.
  86. Shapiro R, Eldar S, Sadot E, et al. Appendiceal carcinoid at a large tertiary center: pathologic findings and long-term follow-up evaluation. Am J Surg. 2011; 201(6): 805–808.
  87. Liu E, Telem DA, Hwang J, et al. The clinical utility of Ki-67 in assessing tumor biology and aggressiveness in patients with appendiceal carcinoids. J Surg Oncol. 2010; 102(4): 338–341.
  88. O'Toole D, Ducreux M, Bommelaer G, et al. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer. 2000; 88(4): 770–776.
  89. Vinik AI, Wolin EM, Liyanage N, et al. ELECT Study Group *. EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL. Endocr Pract. 2016; 22(9): 1068–1080.
  90. Ruszniewski P, Valle JW, Lombard-Bohas C, et al. SYMNET study group. Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study. Dig Liver Dis. 2016; 48(5): 552–558.
  91. Orlewska E, Bednarczuk T, Kaminski G, et al. LanroNET study group*. LanroNET, a non-interventional, prospective study to assess the resource utilization and cost of lanreotide autogel 120 mg in Polish patients with neuroendocrine tumors - results of interim analysis. Contemp Oncol (Pozn). 2014; 18(6): 442–447.
  92. Wolin EM, Jarzab B, Eriksson B, et al. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues. Drug Des Devel Ther. 2015; 9: 5075–5086.
  93. Pavel M, Hörsch D, Caplin M, et al. Telotristat etiprate for carcinoid syndrome: a single-arm, multicenter trial. J Clin Endocrinol Metab. 2015; 100(4): 1511–1519.
  94. Kulke MH, O'Dorisio T, Phan A, et al. Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide. Endocr Relat Cancer. 2014; 21(5): 705–714.
  95. Massimino K, Harrskog O, Pommier S, et al. Octreotide LAR and bolus octreotide are insufficient for preventing intraoperative complications in carcinoid patients. J Surg Oncol. 2013; 107(8): 842–846.
  96. Rinke A, Wittenberg M, Schade-Brittinger C, et al. PROMID Study Group. Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival. Neuroendocrinology. 2017; 104(1): 26–32.
  97. Caplin ME, Pavel M, Ćwikła JB, et al. CLARINET Investigators. Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study. Endocr Relat Cancer. 2016; 23(3): 191–199.
  98. Strosberg J, El-Haddad G, Wolin E, et al. NETTER-1 Trial Investigators. Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017; 376(2): 125–135.
  99. Buscombe JR, Cwikla JB, Caplin ME, et al. Long-term efficacy of low activity meta-[131I]iodobenzylguanidine therapy in patients with disseminated neuroendocrine tumours depends on initial response. Nucl Med Commun. 2005; 26(11): 969–976.
  100. Yao JC, Fazio N, Singh S, et al. RAD001 in Advanced Neuroendocrine Tumours, Fourth Trial (RADIANT-4) Study Group. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016; 387(10022): 968–977.
  101. Fine RL, Gulati AP, Krantz BA, et al. Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience. Cancer Chemother Pharmacol. 2013; 71(3): 663–670.
  102. Berruti A, Fazio N, Ferrero A, et al. Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the XELBEVOCT study. BMC Cancer. 2014; 14: 184.
  103. Koumarianou A, Kaltsas G, Kulke MH, et al. Temozolomide in Advanced Neuroendocrine Neoplasms: Pharmacological and Clinical Aspects. Neuroendocrinology. 2015; 101(4): 274–288.
  104. McCusker ME, Coté TR, Clegg LX, et al. Primary malignant neoplasms of the appendix: a population-based study from the surveillance, epidemiology and end-results program, 1973-1998. Cancer. 2002; 94(12): 3307–3312.
  105. McGory ML, Maggard MA, Kang H, et al. Malignancies of the appendix: beyond case series reports. Dis Colon Rectum. 2005; 48(12): 2264–2271.
  106. Taggart MW, Abraham SC, Overman MJ, et al. Goblet cell carcinoid tumor, mixed goblet cell carcinoid-adenocarcinoma, and adenocarcinoma of the appendix: comparison of clinicopathologic features and prognosis. Arch Pathol Lab Med. 2015; 139(6): 782–790.
  107. Mahteme H, Sugarbaker PH. Treatment of peritoneal carcinomatosis from adenocarcinoid of appendiceal origin. Br J Surg. 2004; 91(9): 1168–1173.
  108. McConnell YJ, Mack LA, Gui X, et al. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: an emerging treatment option for advanced goblet cell tumors of the appendix. Ann Surg Oncol. 2014; 21(6): 1975–1982.
  109. OCEBM Levels of Evidence Working Group*. “The Oxford 2011 Levels of Evidence”. Ox-ford Centre for Evidence-Based Medicine. http://www. cebm.net/index.aspx?o=5653
  110. Knigge U, Capdevila J, Bartsch DK et al. ENETS Consensus recommendations for standards of care in neuroendocrine neoplasms: follow-up and documentation. Neuroendocrinology 2017: (in press)

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl